

Financial Tear Sheet

Corporate Profile

We are a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of patients in the physician office setting or operating room who are suffering from chronic sinusitis. Our XprESS family of products is used by ear, nose and throat, or ENT, physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses.

Recent Headlines

| | |
|----------|---|
| 12/07/17 | Entellus Medical Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of \$24.00 Per Share in Cash |
| 11/14/17 | Entellus Medical to Participate in Upcoming Investor Conferences |
| 11/13/17 | Anthem Inc. Issues Positive Coverage Decision for Balloon Sinus Dilation |

Upcoming Events

There are currently no events scheduled.

SEC Filings

| FILING DATE | FORM |
|-------------|--------------------------|
| 02/15/18 | SC 13G/A |
| 01/24/18 | DEFM14A |
| 01/09/18 | 4 |
| 01/09/18 | 4 |

Corporate Governance

| | |
|---------------------------------------|---------------------------------------|
| Robert S. White | President and CEO |
| Brent A. Moen | CFO |
| Michael H. Rosenthal | Chief Operating Officer |
| Donald Gonzales, M.D. | Chief Medical Officer |
| Thomas P. Williamson | Vice President, Commercial Operations |

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)